Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials
Open Access
- 21 December 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Drug Investigation
- Vol. 36 (3), 177-194
- https://doi.org/10.1007/s40261-015-0361-z
Abstract
Iron deficiency is very common in a number of medical conditions. Ferric carboxymaltose is a new stable iron preparation that can be administered in single infusions over short periods of time. The aim of this study was to conduct a systematic review of randomised controlled trials (RCTs) regarding the efficacy and safety of the novel complex compared with other iron formulations. In addition, the feasibility of a network meta-analysis for indirect comparisons was investigated. A systematic literature review was performed for published RCTs on the use of ferric carboxymaltose in iron deficiency between July and October 2014. Indirect comparisons were also addressed using terms referring to competing iron formulations. We further supported the qualitative results of the systematic review by a network meta-analysis that allows pooling the evidence around different intervention outcomes in the absence of trials involving a direct comparison. The initial search yielded 1027 citations, which was decreased to 21 studies eligible for inclusion in the review. Studies were heterogeneous in the number of patients randomised, iron deficiency-related conditions addressed, trial inclusion criteria, time horizon, treatment dosage and outcomes assessed. Six studies with the same time horizon (i.e. 6 weeks) were included in the network meta-analysis. Considering the differences between final and initial outcome values for each iron formulation, the mean difference of these differences (delta) was estimated for each couple of treatments involving ferric carboxymaltose. Significant improvements in serum ferritin (µg/l) were obtained with ferric carboxymaltose compared to oral iron (delta 172.8; 95 % CI 66.7–234.4) and in haemoglobin (g/dl) with respect to ferric gluconate (delta 0.6; 95 % CI 0.2–0.9), oral iron (delta 0.8; 95 % CI 0.6–0.9) and placebo (delta 2.1; 95 % CI 1.2–3.0). All currently available intravenous iron preparations appear to be safe and effective, but ferric carboxymaltose seems to provide a better and quicker correction of haemoglobin and serum ferritin levels in iron-deficient patients.Keywords
This publication has 48 references indexed in Scilit:
- Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR‐HF trial: an analysis for the UKEuropean Journal of Heart Failure, 2012
- Patient blood management in EuropeBritish Journal of Anaesthesia, 2012
- Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial dataBMC Blood Disorders, 2011
- Clinical Use of Intravenous Iron: Administration, Efficacy, and SafetyHematology-American Society Hematology Education Program, 2010
- Indirect Comparisons: A Review of Reporting and Methodological QualityPLOS ONE, 2010
- A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patientsNephrology Dialysis Transplantation, 2010
- A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndromeSleep Medicine, 2009
- Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trialAmerican Journal of Obstetrics and Gynecology, 2008
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004